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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.009Remyelination occurs in multiple sclerosis (MS) lesions but is generally considered to be insufﬁcient.
One of the major challenges in MS research is to understand the causes of remyelination failure and to
identify therapeutic targets that promote remyelination. Activation of pancreatic endoplasmic reticu-
lum kinase (PERK) signaling in response to endoplasmic reticulum stress modulates cell viability and
function under stressful conditions. There is evidence that PERK is activated in remyelinating oligo-
dendrocytes in demyelinated lesions in both MS and its animal model, experimental autoimmune
encephalomyelitis (EAE). In this study, we sought to determine the role of PERK signaling in remye-
linating oligodendrocytes in MS and EAE using transgenic mice that allow temporally controlled acti-
vation of PERK signaling speciﬁcally in oligodendrocytes. We demonstrated that persistent PERK
activation was not deleterious to myelinating oligodendrocytes in young, developing mice or to
remyelinating oligodendrocytes in cuprizone-induced demyelinated lesions. We found that
enhancing PERK activation, speciﬁcally in (re)myelinating oligodendrocytes, protected the cells and
myelin against the detrimental effects of interferon-g, a key proinﬂammatory cytokine in MS and
EAE. More important, we showed that enhancing PERK activation in remyelinating oligodendrocytes
at the recovery stage of EAE promoted cell survival and remyelination in EAE demyelinated lesions.
Thus, our data provide direct evidence that PERK activation cell-autonomously enhances the survival
and preserves function of remyelinating oligodendrocytes in immune-mediated demyelinating dis-
eases. (Am J Pathol 2014, 184: 507e519; http://dx.doi.org/10.1016/j.ajpath.2013.10.009)Supported by National Multiple Sclerosis Society grants TA3026-A-1 and
RG4813-A-2 (W.L.) and NIH grant NS073132 (W.L.). D.R. is a Principal
Research Fellow of the Wellcome Trust.Multiple sclerosis (MS) is a chronic inﬂammatory demye-
linating disease in the central nervous system (CNS).
Regeneration of oligodendrocytes and subsequent remyeli-
nation are necessary to restore neurological function in pa-
tients with MS. Although the remyelination process occurs in
the CNS of patients with MS, this remyelination is generally
considered to be insufﬁcient.1,2 Increasingly, the evidence
suggests that endoplasmic reticulum (ER) stress, which is
caused by the accumulation of unfolded or misfolded pro-
teins in the ER, plays a role in inﬂammatory diseases,
including MS and its animal model, experimental autoim-
mune encephalomyelitis (EAE).3e5 Activation of pancreatic
ER kinase (PERK) in response to ER stress promotes a stress-
resistant state through the global attenuation of proteinstigative Pathology.
.translation and the induction of numerous cytoprotective
genes. PERK activation, however, also triggers an apoptotic
program to eliminate ER-stressed cells.6,7 Although PERK
activation has been observed in oligodendrocytes in MS and
EAE demyelinated lesions,8e10 the role that PERK signaling
plays in remyelinating oligodendrocytes during the remye-
lination process remains elusive.
Recently, we generated PLP/Fv2E-PERK transgenic mice
that allow temporally controlled activation of PERK sig-
naling speciﬁcally in oligodendrocytes. By using the unique
Lin et almouse model, we found that enhanced activation of PERK
signaling speciﬁcally in mature oligodendrocytes protected
the cells and myelin against inﬂammatory attack in EAE
mice.11 Mature oligodendrocytes in adult mice are only
responsible for the slow replenishment of myelin compo-
nents. In contrast, remyelinating oligodendrocytes must
synthesize enormous amounts of membrane lipid and pro-
tein molecules to assemble myelin sheaths. The cells have
extremely high metabolic rates.4,12 This feature makes
remyelinating oligodendrocytes in MS and EAE demyeli-
nated lesions more vulnerable to inﬂammatory attack and
ER stress than mature oligodendrocytes.12,13 Our previous
studies have shown that ER stress, induced by interferon-g
(IFN-g), protects mature oligodendrocytes and myelin
against inﬂammatory attack during the acute stage of EAE,
but causes remyelinating oligodendrocyte apoptosis and
remyelination failure at the recovery stage of EAE.8,14 Thus,
in this study, we sought to dissect the precise role of PERK
signaling in remyelinating oligodendrocytes in immune-
mediated demyelinating diseases exploiting PLP/Fv2E-
PERK mice.
The immune cytokine, IFN-g, is thought to be a major
contributing factor to poor remyelination in MS lesions.1,13
Our previous studies have shown that the presence of IFN-g
in the CNS causes hypomyelination in young, developing
mice, and remyelination failure in the cuprizone and EAE
models.14,15 In this study, we demonstrate that persistent
activation of PERK signaling does not affect the viability or
function of (re)myelinating oligodendrocytes under normal
conditions. Moreover, we show that enhancing PERK
activation speciﬁcally in (re)myelinating oligodendrocytes
attenuates IFN-geinduced hypomyelination in young,
developing mice and IFN-geinduced remyelination failure
in the cuprizone model. More important, we ﬁnd that
enhancing PERK activation speciﬁcally in remyelinating
oligodendrocytes promotes remyelination in the EAE
model. Our ﬁndings may lead to the development of ther-
apeutic interventions to improve remyelination in patients
with MS.
Materials and Methods
Mice, Cuprizone Treatment, and EAE Immunization
All mouse lines used were on the C57BL/6J background.
PLP/Fv2E-PERK transgenic mice were maintained by
mating with C57BL/6J mice.11 GFAP/tTA;TRE/IFN-g;
PLP/Fv2E-PERK triple transgenic mice were produced by
crossing line 110 GFAP/tTA mice14e16 with PLP/Fv2E-
PERK mice, and then crossing the resulting progeny with
line 184 TRE/IFN-g mice.14e16 To repress the expression of
the IFN-g transgene in the astrocytes of GFAP/tTA;TRE/
IFN-g;PLP/Fv2E-PERK mice, 0.05 mg/mL doxycycline
was added to the drinking water and provided ad libitum
from conception.14e16 To activate the Fv2E-PERK trans-
gene in the oligodendrocytes of PLP/Fv2E-PERK mice, the508mice were given daily i.p. injections of AP20187 (Ariad
Pharmaceuticals, Cambridge, MA); controls were injected
with vehicle (4% ethanol, 10% PEG-400, and 2.0% Tween-
20 in water) only.11
To induce demyelination with cuprizone, 6-weekeold
male mice were fed a diet of mouse chow containing 0.2%
cuprizone (Sigma-Aldrich, St. Louis, MO) for up to 6
weeks. Subsequently, mice were returned to a normal diet
for 3 weeks to allow remyelination to occur.14 To induce
EAE, 7-weekeold female mice were injected s.c. in the
ﬂank and at the tail base with 200 mg of myelin oligoden-
drocyte glycoprotein 35 to 55 peptideeemulsiﬁed incom-
plete Freund’s adjuvant (BD Biosciences, San Jose, CA)
supplemented with 600 mg of Mycobacterium tuberculosis
(strainH37Ra; BD Biosciences). Two i.p. injections of 400
ng pertussis toxin (List Biological Laboratories, Denver,
CO) were given 24 and 72 hours later. Clinical scores (0
indicates healthy; 1, ﬂaccid tail; 2, ataxia and/or paresis of
hind limbs; 3, paralysis of hind limbs and/or paresis of
forelimbs; 4, tetra paralysis; and 5, moribund or death) were
recorded daily.8,11
All animal procedures were conducted in complete
compliance with the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of the University of South
Alabama (Mobile) and the University of Minnesota
(Minneapolis).
Real-Time PCR
Deeply anesthetized mice were perfused with ice-cold PBS.
RNA was isolated from the brain or the spinal cord using
TRIzol reagent (Invitrogen, Carlsbad, CA) and treated with
DNaseI (Invitrogen) to eliminate genomic DNA. Reverse
transcription was performed using the iScript cDNA Syn-
thesis Kit (Bio-Rad Laboratories, Hercules, CA). TaqMan
real-time PCR was performed with iQSupermix (Bio-Rad
Laboratories) on a Bio-Rad iQ Real-Time PCR detection
system, as previously described.8,14,17
Western Blot Analysis
Tissues harvested from mice were rinsed in ice-cold PBS and
were homogenized using a motorized homogenizer, as pre-
viously described.15,18 After incubating on ice for 15 min-
utes, the extracts were cleared by centrifugation at 18,000 g
for 30 minutes, twice. The protein content of each extract was
determined by DC Protein Assay (Bio-Rad Laboratories).
Extracts (40 mg) were separated by SDS-PAGE and trans-
ferred to nitrocellulose. The blots were incubated with a
primary antibody against myelin basic protein (MBP;
1:1000; Sternberger Monoclonals, Berkeley, CA), proteoli-
pid protein (PLP; 1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA), or b-actin (1:5000; Sigma-Aldrich). This was
followed by a horseradish peroxidaseeconjugated sec-
ondary antibody; after incubation with the ECL Detectionajp.amjpathol.org - The American Journal of Pathology
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chemiluminescent signal was detected. The intensity of the
recorded chemiluminescence signal was quantiﬁed with
Kodak 1D Image Analysis software version 3.6 (Kodak,
Hercules, New Haven, CT).
IHC and TUNEL Staining
Anesthetized mice were perfused through the left cardiac
ventricle with 4%paraformaldehyde in PBS. The tissues were
removed, postﬁxed with paraformaldehyde, cryopreserved in
30% sucrose, embedded in optimal cutting temperature
compound, and frozen on dry ice. Frozen sections were cut
using a cryostat (10 mm thick). For immunohistochemistry
(IHC), the sectionswere treatedwith20C acetone, blocked
with PBS containing 10%goat serum and 0.1%TritonX-100,
and incubated overnight with the primary antibody diluted in
blocking solution. Fluorescein, Cy3, or enzyme-labeled sec-
ondary antibodies (Vector Laboratories, Burlingame, CA)
were used for detection. IHC detection of CC1 (Adenomatus
Polyposis Coli 7, 1:50; EMD Biosciences, Gibbstown, NJ),
platelet-derived growth factor a receptor (PDGFaR; 1:100;
Millipore, Temecula, CA), phosphorylated translation initi-
ation factor 2a (p-eIF2a; 1:100; Cell Signaling Technology,
Danvers, MA), MBP (1:1000; Sternberger Monoclonals),
CD3 (1:50; Santa Cruz Biotechnology), CD11b (1:50; Mil-
lipore), and aspartoacylase (ASPA; 1:1000; kindly provided
by Dr. M.A. Aryan Namboodiri at Uniformed Services Uni-
versity of the Health Sciences, Bethesda, MD) were per-
formed. Fluorescent-stained sections were mounted with
Vectashield mounting medium with DAPI (Vector Labora-
tories) and visualized with a Nikon A1 confocal microscope
(Nikon Instruments, Inc., Melville, NY), an Olympus
FV1000 confocal microscope (Olympus America, Inc.,
Center Valley, PA), or a Zeiss Axioskop 2 ﬂuorescence mi-
croscope (Carl Zeiss Microscopy, Thornwood, NY).
TUNEL staining was performed using the ApopTag kit
(Chemicon, Temecula, CA), according to the manufac-
turer’s instructions. The sections were mounted with Vec-
tashield mounting medium with DAPI (Vector Laboratories)
and visualized with a Nikon A1 confocal microscope or an
Olympus FV1000 confocal microscope.
For cuprizone-treated mice, coronal sections of the fornix
region of the corpus callosum, corresponding to Sidman
sections 241 to 251, were selected for use, and all
comparative analyses were restricted to the midline corpus
callosum.19 We quantiﬁed immunopositive cells by count-
ing positive cells within the median of the corpus callosum,
conﬁned to an area of 0.15 mm2. We scored each slide
immunostained for MBP on a scale of 0 to 4. A score of
0 indicated complete demyelination, and a score of 4 indi-
cated normal myelination in the corpus callosum of adult
mice.14 For EAE mice, we counted immunopositive cells
within the anterior funiculus directly medial to the anterior
median ﬁssure in the lumbar spinal cord and conﬁned to an
area of 0.1 mm2, as described in our previous articles.8,11The American Journal of Pathology - ajp.amjpathol.orgToluidine Blue Staining and Electron Microscopy
Analysis
Mice were anesthetized and perfused with PBS contain-
ing 4% paraformaldehyde and 2.5% glutaraldehyde. For
cuprizone-treated mice, brains were sliced into sections
(1 mm thick). The section corresponding to the region of the
fornix was trimmed, processed for electron microscopic
(EM) analysis, and oriented so that a cross section of the
corpus callosum was achieved. Ultrathin sections were cut,
stained with uranyl acetate and lead citrate, and analyzed as
described previously.14 For EAE mice, the lumbar spinal
cord was processed and embedded. Thin sections were cut,
stained with toluidine blue, and analyzed as described pre-
viously.11 Moreover, ultrathin sections were cut, stained with
uranyl acetate and lead citrate, and analyzed as described
previously.11 We counted the total number of axons, calcu-
lated the total percentage of remyelinated axons, and
measured the diameter of axons and the thickness of myelin
sheaths using NIH ImageJ software version 1.45S (http://rsb.
info.nih.gov/ij, last accessed November 1, 2012; NIH,
Bethesda, MD), as described previously.14,17
Statistics
Data are expressed as means  SD. For quantitative histo-
logical analyses, the average number for each mouse was
used for statistical analysis. If the data followed the gaussian
distribution, multiple comparisons were statistically evalu-
ated by the one-way analysis of variance test, followed by
Tukey’s test, and comparison of two groups was statistically
evaluated by two-tailed t-test using SigmaStat 3.1 software
(Hearne Scientiﬁc Software, Chicago, IL). If the data did not
follow the gaussian distribution, a multiple comparison was
statistically evaluated by the Kruskal-Wallis test, followed by
a Dunns test, and comparison of two groups was statistically
evaluated by the Mann-Whitney test using SigmaStat 3.1
software. Phenotypic differences among the groups were
statistically evaluated by the c2 test using SigmaStat 3.1
software. The relationship between myelin thickness and
axon diameter was statistically evaluated by a linear regres-
sion using SigmaStat 3.1 software. P < 0.05 was considered
signiﬁcant.
Results
Persistent Activation of PERK Signaling Does Not
Affect the Function of Myelinating Oligodendrocytes in
Young, Developing Mice
In response to ER stress, PERK is activated through
dimerization and autophosphorylation, enabling it to phos-
phorylate eIF2a.20,21 Phosphorylation of eIF2a inhibits
global protein synthesis, but stimulates the expression of
certain stress-induced genes, such as CCAAT enhancer
binding protein homologous protein (CHOP) and growth509
Figure 1 Persistent activation of PERK signaling in myelinating oligo-
dendrocytes does not affect developmental myelination. A: Real-time PCR
analysis shows that AP20187 treatment signiﬁcantly increases the expres-
sion of CHOP and GADD34 in the spinal cord of 21-day-old PLP/Fv2E-PERK
mice, but does not affect the expression of binding immunoglobulin protein
(BIP). NZ 3 animals. Error bars represent SD. B:Western blot analysis shows
that AP20187 treatment does not affect the protein levels of MBP and PLP in
the brain of 21-day-old PLP/Fv2E-PERK mice. NZ 3 animals. C: CC1 and p-
eIF2a double immunostaining shows that p-eIF2a immunoreactivity is un-
detectable in oligodendrocytes in the brain of 21-day-old PLP/Fv2E-PERK
mice treated with vehicle, but becomes detectable in oligodendrocytes
(arrows) in AP20187-treated mice. Black bars, AP20187; gray bars, vehicle.
NZ 3 animals. *P < 0.05. Scale barZ 20 mm (C).
Lin et alarrest and DNA damage 34 (GADD34), by promoting the
translation of the cytosolic transcription factor ATF4. We
have generated PLP/Fv2E-PERK transgenic mice that allow
temporally controlled activation of PERK signaling specif-
ically in oligodendrocytes in the absence of ER stress.11
These mice express Fv2E-PERK, an artiﬁcial PERK that
is generated by fusing the eIF2a kinase effector domain of
PERK to a polypeptide containing two modiﬁed FK506
binding domains (Fv2E),22 under the control of the mouse
PLP transcriptional control region.23,24 We have demon-
strated that PLP/Fv2E-PERK mice express the transgene
product Fv2E-PERK speciﬁcally in oligodendrocytes and
that the activity of Fv2E-PERK is tightly controlled by
administration of the dimerizer AP20187.11
Robust myelination occurs in the mouse CNS between
postnatal day (P) 7 and P21.25 To determine whether PERK
activation affects the myelinating function of oligodendro-
cytes, PLP/Fv2E-PERK mice were treated with 2 mg/kg
AP20187 daily starting on P12 and ending on P21.
AP20187-treated transgenic mice were indistinguishable
from littermate transgenic mice treated with vehicle and
from untreated wild-type mice. Real-time PCR analysis
showed that AP20187 treatment signiﬁcantly enhanced the
expression of the PERK-responsive genes CHOP and
GADD34 in the CNS of the transgenic mice (Figure 1A),
but did not alter the expression of binding immunoglobulin
protein, an ER stress-inducible gene not regulated by PERK
signaling.26 Meanwhile, Western blot analysis showed that
AP20187 treatment did not change the levels of MBP and
PLP in the CNS of 21-day-old PLP/Fv2E-PERK mice
(Figure 1B). CC1 (a marker for oligodendrocytes) and
p-eIF2a double immunostaining showed that AP20187
treatment markedly increased the level of p-eIF2a in most
oligodendrocytes in the CNS of 21-day-old PLP/Fv2E-
PERK mice (Figures 1C and 2I). Interestingly, we found
that AP20187 treatment did not change the number of oli-
godendrocytes in the CNS of 21-day-old PLP/Fv2E-PERK
mice (Figures 1C and 2J). Collectively, these data indicate
that AP20187 treatment results in PERK activation in oli-
godendrocytes at non-physiological levels in transgenic
mice with enforced expression of Fv2E-PERK speciﬁcally
in oligodendrocytes, and that persistent activation of PERK
signaling speciﬁcally in myelinating oligodendrocytes does
not affect their viability or function.
Enhancing PERK Activation in Myelinating
Oligodendrocytes Ameliorates IFN-geInduced
Hypomyelination
IFN-g is thought to be a key proinﬂammatory cytokine in
MS and EAE.13,27 We have generated transgenic mice that
allow controllable delivery of IFN-g to the CNS using the
tetracycline-controllable system.16 Our previous studies
have shown that the presence of IFN-g in the CNS during
development causes oligodendrocyte loss and hypomyeli-
nation and that PERK signaling enhances the viability510of myelinating oligodendrocytes in IFN-geexpressing
mice.15,18 It has been well documented that the presence
of IFN-g in the CNS reduces the viability of oligodendrocytes
by activating T cells and microglia/macrophages.28,29 More-
over, recent studies have shown that PERK signaling in-
ﬂuences the activity of T cells and macrophages.30,31 Thus, it
is not clear whether the protective effects of PERK signaling
on oligodendrocytes in IFN-geexpressing mice are the result
of its actions in oligodendrocytes or in inﬂammatory cells.
To determine the cell-autonomous role of PERK signaling
in myelinating oligodendrocytes in response to IFN-g,
GFAP/tTA mice were crossed with PLP/Fv2E-PERK mice,ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Enhancing PERK activation in myeli-
nating oligodendrocytes protects the cells and
myelin against IFN-g in young, developing mice.
AeD and J: CC1 immunostaining shows that AP20187
treatment does not alter the number of oligoden-
drocytes in the corpus callosum of 21-day-old control
mice, but signiﬁcantly attenuates IFN-geinduced
oligodendrocyte loss in IFN-geexpressing mice. NZ
3 animals. EeH: MBP immunostaining shows that
AP20187 treatment does not affect the degree of
myelination in the corpus callosum of 21-day-old
control mice, but ameliorates IFN-geinduced myelin
loss in IFN-geexpressingmice. NZ 3 animals. I: CC1
and p-eIF2a double immunostaining shows that the
presence of IFN-g in the CNSmoderately increases the
percentage of CC1-positive cells that are double
positive for CC1 and p-eIF2a in the corpus callosum of
21-day-old vehicle-treated mice (IFN-gþ; vehicle
mice versus IFN-g; vehiclemice), and that>80%of
oligodendrocytes are p-eIF2a positive in the corpus
callosum of 21-day-old AP20187-treated mice
(IFN-g; AP20187 mice and IFN-gþ; AP20187
mice). NZ 3 animals. K and L: Western blot analysis
showsthatAP20187 treatmentdoesnot alter the level
of MBP in the brain of 21-day-old control mice, but
signiﬁcantly attenuates the reduction of MBP level in
mice expressing IFN-g. The MBP protein level is re-
ported relative to b-actin. NZ 3 animals. I, J, and L:
Error bars represent SD. *P< 0.05. Scale bars: 20 mm
(AeD); 50 mm (EeH).
PERK in Remyelinating Oligodendrocytesand the resulting progeny were crossed with TRE/IFN-gmice
to obtain GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK triple
transgenic mice. The triple transgenic mice were treated
with doxycycline from conception to repress transgenic
IFN-g expression. One group of the triple transgenic mice
released from doxycycline at embryonic day 14 (E14) was
treated with 0.5 mg/kg AP20187 daily starting on P12 (IFN-
gþ; AP20187 mice). A second group of the triple transgenic
mice released from doxycycline at E14 was treated with
vehicle (IFN-gþ; vehicle mice). The triple transgenic mice
never released from doxycycline were treated with either
AP20187 or vehicle to serve as controls (IFN-g; AP20187
mice and IFN-g; vehicle mice, respectively). IFN-gþ;
vehicle mice exhibited tremor and ataxia, as described in our
previous articles.15,17,18 Interestingly, IFN-gþ; AP20187
Table 1 IFN-gþ; AP20187 Mice Display a Signiﬁcantly Milder Tremor
Variable No tremor (%)
IFN-g; vehicle mice (n Z 30 animals) 100
IFN-g; AP20187 mice (n Z 15 animals) 100
IFN-gþ; vehicle mice (n Z 27 animals) 0
IFN-gþ; AP20187 mice (n Z 12 animals) 0
Mild tremor indicates tremor only in the tail; tremor, tremor in the tail and bo
*P < 0.05.
The American Journal of Pathology - ajp.amjpathol.orgmice displayed a signiﬁcantly milder tremoring phenotype
than IFN-gþ; vehicle mice (Table 1).
As expected, CC1 and p-eIF2a double immunostaining
showed that AP20187 treatment increased the level of
p-eIF2a in oligodendrocytes in control mice and IFN-ge
expressing mice (Figure 2I). We also found that, although
AP20187 treatment did not affect oligodendrocyte numbers
in the CNS of 21-day-old control animals (Figure 2, A, B,
and J), it did attenuate oligodendrocyte loss in the CNS of
21-day-old IFN-geexpressing mice (Figure 2, C, D, and J).
Moreover, MBP immunostaining and Western blot analyses
showed that AP20187 treatment did not affect the myeli-
nation process in the CNS of control animals, but signiﬁ-
cantly alleviated myelin loss in the CNS of 21-day-old
IFN-geexpressing mice (Figure 2, EeH, K, and L). Inthan IFN-gþ; Vehicle Mice





dy; and severe tremor, whole body tremor and occasional seizure.
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Lin et aladdition, PDGFaR immunostaining showed that AP20187
treatment did not signiﬁcantly alter the number of oligo-
dendrocyte progenitor cells (OPCs) in the CNS of 21-day-
old control mice or IFN-geexpressing mice (data not
shown). Collectively, these data suggest that enhancing
PERK activation in myelinating oligodendrocytes protects
the cell and myelin against the cytotoxicity of IFN-g,
resulting in the attenuation of the tremoring phenotype in
the mice.
Our previous study demonstrated that inﬂammatory cells
(T cells and microglia/macrophages) do not express the
transgene product Fv2E-PERK in PLP/Fv2E-PERK mice.11
Moreover, recent studies have shown that AP20187 has no
noticeable effect on the functions of inﬂammatory cells.11,32
Therefore, we further sought to exclude the possibility that
AP20187 treatment inﬂuences the IFN-geinduced inﬂam-
matory response in GFAP/tTA;TRE/IFN-g;PLP/Fv2E-
PERK mice. As expected, we found that AP20187 treatment
did not signiﬁcantly affect the expression of IFN-g in the
CNS of control mice or IFN-geexpressing mice (Figure 3I).
Consistent with our previous studies,17,18 we found that the
presence of IFN-g in the CNS moderately recruited T cellsFigure 3 Enhancing PERK activation speciﬁcally in oligodendrocytes does not
munostaining shows few inﬁltrating T cells (arrows) in the corpus callosum of 21-d
IFN-g; AP20187 mice. Moreover, the numbers of inﬁltrating T cells observed in IFN
animals. EeH: CD11b immunostaining shows that the presence of IFN-g dramaticall
gþ; vehicle mice compared with control IFN-g; vehicle mice or IFN-g; AP20187
AP20187 and IFN-gþ; vehicle mice. NZ 3 animals. I: Real-time PCR analysis revea
IFN-gþ; vehicle mice compared with control IFN-g; vehicle mice or IFN-g; AP20
the levels of IFN-g or TNF-a in the brain of IFN-geexpressing mice. NZ 3 animal
512into the CNS, markedly activated microglia/macrophages,
and dramatically increased the expression of TNF-a
(Figure 3). Nevertheless, AP20187 treatment did not
signiﬁcantly alter T-cell recruitment, microglia/macrophage
activation, or TNF-a expression in the CNS of 21-day-old
control mice or IFN-geexpressing mice. Therefore, it is
unlikely that AP20187 treatment attenuates the IFN-ge
induced oligodendrocyte loss and hypomyelination in
GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK mice by altering
the inﬂammatory response. Taken together, these results
demonstrate that PERK activation cell-autonomously pre-
serves the survival and function of myelinating oligoden-
drocytes in response to IFN-g.
Persistent Activation of PERK Signaling Does Not
Affect the Function of Remyelinating Oligodendrocytes
Derived from OPCs in Adult Mice
Although the cellular mechanisms responsible for remyeli-
nation and developmental myelination share many similar-
ities, multiple lines of evidence suggest they also differ in
several important ways.33 Therefore, we investigated whetheralter the inﬂammatory response in IFN-geexpressing mice. AeD: CD3 im-
ay-old IFN-gþ; vehicle mice compared with control IFN-g; vehicle mice or
-gþ; AP20187 mice are comparable to those in IFN-gþ; vehicle mice. NZ 3
y activates microglia/macrophages in the corpus callosum of 21-day-old IFN-
mice. The level of microglia/macrophage activation is comparable in IFN-gþ;
ls dramatically increased levels of IFN-g and TNF-a in the brain of 21-day-old
187 mice. More important, AP20187 treatment does not signiﬁcantly change
s. Error bars represent SD. Scale bars: 20 mm (AeD); 50 mm (EeH).
ajp.amjpathol.org - The American Journal of Pathology
PERK in Remyelinating Oligodendrocytespersistent activation of PERK signaling is detrimental to
remyelinating oligodendrocytes derived from OPCs in adult
mice using the cuprizone model. When young adult C57BL/
6J male mice are fed 0.2% cuprizone in their diet, mature
oligodendrocytes in the corpus callosum are lost, which is
followed by complete demyelination by 5 weeks of cupri-
zone exposure. OPCs accumulate within the demyelinated
lesion, and mature oligodendrocytes repopulate the area
beginning at approximately 6 weeks into the treatment
protocol, resulting in complete remyelination after several
weeks of cuprizone removal.34 It is generally believed that
the cuprizone model is one of the best mouse models to
understand the processes of demyelination and remyelina-
tion in the CNS. Recently, the cuprizone model is increas-
ingly used to study the mechanisms of remyelination in
demyelinating diseases of the CNS, such as MS.35,36
Six-week-old male PLP/Fv2E-PERK mice on the C57BL/
6J background were treated with 0.2% cuprizone chow for up
to 6 weeks. To determine whether PERK activation in mature
oligodendrocytes affects cuprizone-induced demyelination,
PLP/Fv2E-PERKmicewere treatedwith 0.5mg/kgAP20187
or vehicle daily starting 2 days before cuprizone exposure. In
accordance with previous studies,34 there was almost com-
plete oligodendrocyte loss and demyelination in the corpus
callosum of vehicle-treated mice after 5 weeks of cuprizone
treatment (data not shown). We found that AP20187 treat-
ment did not alter oligodendrocyte loss or demyelination in
the corpus callosum of PLP/Fv2E-PERK mice after 5 weeks
of cuprizone treatment (data not shown). Therefore, these
data suggest that PERK activation speciﬁcally in matureThe American Journal of Pathology - ajp.amjpathol.orgoligodendrocytes has no effect on cuprizone-induced oligo-
dendrocyte loss and demyelination.
To determine the effects of PERK activation on remye-
linating oligodendrocytes, PLP/Fv2E-PERK mice, which
had been treated with 0.2% cuprizone chow for 6 weeks,
were subsequently returned to a normal diet for 3 weeks to
allow remyelination to occur. The Fv2E-PERK was acti-
vated in remyelinating oligodendrocytes by the daily
administration of 0.5 mg/kg AP20187 starting on the day of
cuprizone removal. Controls were injected with vehicle
only. As expected, CC1 and p-eIF2a double immunostain-
ing showed that AP20187 treatment markedly increased the
level of p-eIF2a speciﬁcally in oligodendrocytes in the
corpus callosum (Supplemental Figure S1A). Moreover, we
found that AP20187 treatment did not signiﬁcantly affect
the number of remyelinating oligodendrocytes or the degree
of remyelination in the demyelinated lesions after 3 weeks
of cuprizone removal (Supplemental Figure S1 and
Figures 4 and 5). Thus, these data indicate that the persistent
activation of PERK signaling in remyelinating oligoden-
drocytes, derived from OPCs in adult mice, does not affect
their viability or function.
Enhancing PERK Activation in Remyelinating
Oligodendrocytes Ameliorates IFN-geInduced
Remyelination Failure in Cuprizone-Induced
Demyelinated Lesions
We have shown that the presence of IFN-g in the CNS
induces remyelinating oligodendrocyte apoptosis andFigure 4 Enhancing PERK activation protects
remyelinating oligodendrocytes against the cyto-
toxicity of IFN-g. AeD: CC1 and TUNEL double im-
munostaining shows that there are markedly fewer
oligodendrocytes and more apoptotic oligodendro-
cytes in the corpus callosum of IFN-gþ; vehicle mice
after 3 weeks of cuprizone removal compared with
control IFN-g; vehicle mice or IFN-g; AP20187
mice. Interestingly, AP20187 treatment noticeably
increases the number of oligodendrocytes and re-
duces the number of apoptotic oligodendrocytes in
IFN-gþ; AP20187 mice compared with IFN-gþ;
vehiclemice. Inset:High-magniﬁcation image shows
a CC1 and TUNEL double-positive cell.NZ 4 animals.
E: Quantitative analysis of CC1-positive cells shows
that AP20187 treatment does not alter the number of
oligodendrocytes in the corpus callosum of control
mice after 3 weeks of cuprizone removal, but signif-
icantly attenuates the reduction of oligodendrocyte
numbers in IFN-geexpressing mice. NZ 4 animals.
F: Quantitative analysis of CC1 and TUNEL double-
positive cells shows that AP20187 treatment does
not signiﬁcantly change the number of apoptotic
remyelinating oligodendrocytes in the corpus cal-
losum of control mice after 3 weeks of cuprizone
removal, but signiﬁcantly reduces the amount of IFN-
geinduced apoptosis of remyelinating oligoden-
drocytes in IFN-geexpressing mice. NZ 4 animals.
*P < 0.05 (E and F). Scale barZ 20 mm (AeD).
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Figure 5 Enhancing PERK activation in
remyelinating oligodendrocytes attenuates IFN-ge
induced remyelination failure in cuprizone-induced
demyelinated lesions. AeD and I: MBP immuno-
staining shows that AP20187 treatment does not
affect the degree of remyelination in the corpus
callosum of control mice after 3 weeks of cuprizone
removal, but signiﬁcantly attenuates IFN-ge
induced remyelination failure in IFN-geexpressing
mice. N Z 4 animals. EeH and J: EM analysis
shows that AP20187 treatment does not signiﬁ-
cantly alter the percentage of remyelinated axons
in the corpus callosum of control mice after 3
weeks of cuprizone removal, but signiﬁcantly at-
tenuates the reduced percentage of remyelinated
axons observed in IFN-geexpressing mice. N Z 4
animals. Error bars represent SD. *P < 0.05. Scale
bars: 20 mm (AeD); 500 nm (EeH).
Lin et alsuppresses remyelination in the demyelinated lesions in the
cuprizone model, and that PERK haploinsufﬁciency
exacerbates IFN-geinduced remyelination failure.14 We
used the cuprizone model to determine whether enhanc-
ing PERK activation in remyelinating oligodendrocytes
would have the opposite effect of promoting cell survival
and remyelination in response to IFN-g. Six-week-old
male GFAP/tTA;TRE/IFN-g;PLP/Fv2E-PERK triple trans-
genic mice that had been maintained on doxycycline from
conception were simultaneously treated with 0.2% cupri-
zone chow and released from doxycycline. The triple
transgenic mice were treated with cuprizone chow for 6
weeks, and then returned to a normal diet for 3 weeks. One
group of these triple transgenic mice was treated with 0.5
mg/kg AP20187 daily starting on the day of cuprizone
removal (IFN-gþ; AP20187 mice). A second group of these
triple-transgenic mice was treated with vehicle (IFN-gþ;
vehicle mice). Triple transgenic mice that were never
released from doxycycline, but were treated with 0.2%
cuprizone chow, followed by daily injections of AP20187
or vehicle starting on the day of cuprizone removal, were
used as controls (IFN-g; AP20187 mice and IFN-g;
vehicle mice, respectively). As expected, we found that
AP20187 treatment elevated the level of p-eIF2a in
remyelinating oligodendrocytes in the corpus callosum of
control animals and IFN-geexpressing mice (data not
shown), and that AP20187 treatment did not signiﬁcantly
alter the number of remyelinating oligodendrocytes or the
degree of remyelination in the corpus callosum of control
animals (Figures 4 and 5).
Consistent with our previous study,14 we found that the
presence of IFN-g in the CNS signiﬁcantly reduced the514number of remyelinating oligodendrocytes and the extent of
remyelination in the corpus callosum of IFN-gþ; vehicle
mice after 3 weeks of cuprizone removal compared with
control IFN-g; AP20187 mice and IFN-g; vehicle mice
(Figures 4 and 5). Interestingly, the number of remyelinat-
ing oligodendrocytes in the corpus callosum of IFN-gþ;
AP20187 mice was signiﬁcantly increased compared with
IFN-gþ; vehicle mice (Figure 4, CeE). Furthermore, CC1
and TUNEL double labeling showed that AP20187 treat-
ment signiﬁcantly reduced the number of apoptotic re-
myelinating oligodendrocytes in the corpus callosum of
IFN-gþ; AP20187 mice after 3 weeks of cuprizone removal
compared with IFN-gþ; vehicle mice (Figure 4, C, D, and
F). MBP immunostaining showed that AP20187 treatment
attenuated the degree of remyelination failure in the
demyelinated lesions of IFN-geexpressing mice after 3
weeks of cuprizone removal (Figure 5, C, D, and I). More
important, EM analysis conﬁrmed that AP20187 treatment
signiﬁcantly increased the percentage of remyelinated axons
in the corpus callosum of IFN-gþ; AP20187 mice after 3
weeks of cuprizone removal compared with IFN-gþ;
vehicle mice (Figure 5, G, H, and J). Nevertheless,
PDGFaR immunostaining showed that AP20187 treatment
did not signiﬁcantly alter the number of OPCs in the corpus
callosum of either control mice or IFN-geexpressing mice
(data not shown). As expected, we also found that AP20187
treatment did not affect T-cell inﬁltration or microglia/
macrophage activation in the corpus callosum of control
animals or IFN-geexpressing mice (data not shown).
Collectively, these data demonstrate that PERK activation in
remyelinating oligodendrocytes promotes cell survival and
remyelination in response to IFN-g.ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Enhancing PERK activation speciﬁcally in oligodendrocytes at
the recovery stage of EAE does not alter the disease severity. Mean clinical
scores were recorded daily: 0, healthy; 1, ﬂaccid tail; 2, ataxia and/or
paresis of hind limbs; 3, paralysis of hind limbs and/or paresis of forelimbs;
4, tetra paralysis; and 5, moribund or death. N Z 12 animals. Error bars
represent SD.
Figure 7 Enhancing PERK activation in remyelinating oligodendrocytes
promotes cell survival and remyelination in EAE-demyelinated lesions. AeC:
ASPA immunostaining shows that AP20187 treatment signiﬁcantly increases
the number of ASPA-positive oligodendrocytes in EAE-demyelinated lesions
in the lumbar spinal cord of PLP/Fv2E-PERK mice at PID34. NZ 8 animals.
Error bars represent SD. D and E: EM analysis shows that AP20187 treatment
markedly increases the number of remyelinated axons in demyelinated le-
sions in the lumbar spinal cord of PLP/Fv2E-PERK mice at PID34. Never-
theless, AP20187 treatment does not signiﬁcantly alter the number of total
axons in demyelinated lesions in PLP/Fv2E-PERK mice. NZ 4 animals. Error
bars represent SD. F: Quantitative EM analysis shows that AP20187 treat-
ment signiﬁcantly increases the percentage of axons that are remyelinated
in demyelinated lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice at
PID34. NZ 4 animals. Error bars represent SD. G: Quantitative EM analysis
shows that AP20187 treatment signiﬁcantly increases the thickness of the
newly formed myelin sheaths of remyelinated axons in demyelinated lesions
in the lumbar spinal cord of PLP/Fv2E-PERK mice at PID34. NZ 4 animals.
*P < 0.05 (C, E, and F). Scale bars: 5 mm (A and B); 1 mm (D).
PERK in Remyelinating OligodendrocytesEnhancing PERK Activation in Remyelinating
Oligodendrocytes Promotes Remyelination in EAE
Demyelinated Lesions
Although several studies have shown that ER stress is
activated in multiple cell types in MS and EAE demyeli-
nated lesions, including oligodendrocytes, T cells, and
microglia/macrophages,8e10,37 the role that ER stress plays
in these cell types during the remyelination process remains
unknown. It is believed that inﬂammatory mediators, such
as immune cytokines and reactive oxygen/nitrogen species,
contribute signiﬁcantly to oligodendrocyte death in MS and
EAE.12,38 Several lines of evidence have suggested that
PERK activation protects cells against these inﬂammatory
mediators and ER stress.11,22 Thus, we further determine the
cell-autonomous role of PERK activation in remyelinating
oligodendrocytes in the EAE model. Seven-week-old fe-
male PLP/Fv2E-PERK mice were immunized with myelin
oligodendrocyte glycoprotein 35 to 55 peptide to induce
EAE. These mice developed neurological signs of disease
starting at approximately postimmunization day (PID) 14,
and started recovering from EAE at approximately PID2211
(Figure 6). Remyelination in MS and EAE demyelinated
lesions has been reported to initiate during the acute stage of
diseases.39,40 To activate PERK signaling in the remyeli-
nating oligodendrocytes within the demyelinated lesions at
the recovery stage of EAE, PLP/Fv2E-PERK mice were
given i.p. injections of 0.5 mg/kg AP20187 daily starting on
PID20; controls were injected with vehicle. CC1 and p-
eIF2a double immunostaining showed that a few oligo-
dendrocytes were p-eIF2a positive in the lumbar spinal cord
of PLP/Fv2E-PERK mice treated with vehicle. As expected,
the level of p-eIF2a was markedly increased in oligoden-
drocytes in PLP/Fv2E-PERK mice treated with AP20187
(Supplemental Figure S2). Nevertheless, AP20187 treat-
ment did not signiﬁcantly change the clinical symptoms of
mice with EAE (Figure 6).
Next,wedeterminedwhetherAP20187 treatment inﬂuences
the viability and function of remyelinating oligodendrocytes inThe American Journal of Pathology - ajp.amjpathol.orgthe demyelinated lesions of PLP/Fv2E-PERK mice. Our pre-
vious studies have shown that oligodendrocytes were largely
lost in EAE demyelinated lesions at the peak of disease.8,11
Immunostaining for ASPA, a marker for oligodendro-
cytes,41,42 showed that at PID34, a few oligodendrocytes were
present in the demyelinated lesions in the lumbar spinal cord of
PLP/Fv2E-PERK mice treated with vehicle. AP20187 treat-
ment signiﬁcantly increased the number of oligodendrocytes in
the demyelinated lesions of PLP/Fv2E-PERK mice at PID34
(Figure 7, AeC); however, there were signiﬁcantly fewer oli-
godendrocytes in the demyelinated lesions ofAP20187-treated
mice than in the matched regions in adult naïve PLP/Fv2E-
PERK mice (Figure 7C and Supplemental Figure S3, AeC).
Furthermore, EM analysis was used to observe remyelinated
axons,which are recognizable bymyelin sheaths that are thin in
relation to axon diameter,12 in the demyelinated lesions at
PID34. Importantly, there were signiﬁcantly more remyeli-
nated axons in the demyelinated lesions of AP20187-treated
mice than of vehicle-treated mice (Figure 7, D and F).
AP20187 treatment also signiﬁcantly increased the myelin
thickness of remyelinated axons in PLP/Fv2E-PERK mice at515
Figure 8 AP20187 treatment does not alter the inﬂammatory response
Lin et alPID34 (Figure 7G). Nevertheless, AP20187 treatment did not
signiﬁcantly change the total number of axons in the demye-
linated lesions of PLP/Fv2E-PERK mice (Figure 7E and
Supplemental Figure S3, DeF). As expected, there were
signiﬁcantly fewer total axons in the demyelinated lesions of
PLP/Fv2E-PERKmice treated with either AP20187 or vehicle
than in the matched regions in adult naïve PLP/Fv2E-PERK
mice (Figure 7E and Supplemental Figure S3, DeF). Mean-
while, PDGFaR immunostaining showed that AP20187
treatment did not signiﬁcantly alter the number of OPCs in the
demyelinated lesions of PLP/Fv2E-PERK mice (data not
shown). Taken together, these data demonstrate that PERK
activation in remyelinating oligodendrocytes promotes cell
survival and remyelination in EAE demyelinated lesions.
There is no evidence that AP20187 treatment alone has
any noticeable effect on mice under physiological or path-
ological conditions.32,43e45 More important, our previous
study demonstrated that AP20187 treatment does not affect
the inﬂammatory response in PLP/Fv2E-PERK mice un-
dergoing EAE.11 Consistently, we found that AP20187
treatment did not signiﬁcantly alter the number of CD3-
positive T cells or the number of CD11b-positive microglia/
macrophages in the demyelinated lesions of PLP/Fv2E-
PERK mice at PID34 (Figure 8). Thus, it is unlikely that
AP20187 treatment promotes remyelination in the EAE
demyelinated lesions of PLP/Fv2E-PERK mice by altering
the inﬂammatory response.in the CNS of PLP/Fv2E-PERK mice undergoing EAE. A, B, and E: CD3 im-
munostaining shows that AP20187 treatment does not affect T-cell (ar-
rows) inﬁltration into the white matter of the lumbar spinal cord in PLP/
Fv2E-PERK mice at PID34. N Z 4 animals. CeE: CD11b immunostaining
shows that AP20187 treatment does not alter the number of microglia/
macrophages present in the white matter of the lumbar spinal cord in PLP/
Fv2E-PERK mice at PID34. NZ 4 animals. E: Error bars represent SD. Black
bars, AP20187; gray bars, vehicle. Scale bars: 20 mm (A and B); 50 mm
(C and D).Discussion
MS is a chronic inﬂammatory demyelinating disease of the
CNS.46 Remyelination is necessary to restore neurological
function in patients with MS; however, the remyelination is
considered to be insufﬁcient.1,2 It is generally believed that
the accumulated load of demyelinated lesions that fail to
remyelinate leads to the progressive deterioration of
neurological function in patients with MS. One of the major
challenges in MS research is to understand the causes of
remyelination failure and to develop therapeutic strategies
that promote oligodendrocyte regeneration and remyelina-
tion. Several lines of evidence have suggested that ER stress
in oligodendrocytes inﬂuences the development of myelin
disorders.4,47 PERK signaling activated in response to ER
stress is essential to preserve cell function and survival
under stressful conditions. Nevertheless, PERK signaling is
not exclusively beneﬁcial to cell survival. Persistent acti-
vation of PERK signaling can result in cell apoptosis
through the induction of CHOP, a pro-apoptotic transcrip-
tion factor, in ER-stressed cells.6,7 Interestingly, a previous
study showed that CHOP induction promotes the survival of
ER-stressed myelinating oligodendrocytes in the mouse
models of Pelizaeus-Merzbacher disease.48 The unique
function of CHOP in myelinating oligodendrocytes raises
the possibility that PERK signaling has particularly beneﬁ-
cial effects on (re)myelinating oligodendrocytes.516Activation of PERK signaling has been observed in oli-
godendrocytes in MS and EAE demyelinated lesions.9,10,37
Nevertheless, the role that it plays in remyelinating oligo-
dendrocytes in these diseases remains ambiguous. We have
generated transgenic mice that allow temporally controlled
activation of PERK signaling speciﬁcally in oligodendro-
cytes.11 In this study, by using the unique mouse model, we
provide direct evidence that PERK activation in remyeli-
nating oligodendrocytes is cytoprotective, promoting
remyelination in demyelinated lesions in immune-mediated
demyelinating diseases. First, we demonstrated that persis-
tent activation of PERK signaling was not deleterious to
myelinating oligodendrocytes in young, developing mice or
to remyelinating oligodendrocytes in cuprizone-induced
demyelinated lesions. Second, we showed that speciﬁcally
enhancing PERK activation in myelinating oligodendro-
cytes protects the cells and myelin against the detrimental
effects of the immune cytokine, IFN-g, during development.
Third, we showed that enhanced PERK activation in
remyelinating oligodendrocytes attenuated IFN-geinducedajp.amjpathol.org - The American Journal of Pathology
PERK in Remyelinating Oligodendrocytescell apoptosis and remyelination failure in the cuprizone
model. Fourth, we showed that enhanced PERK activation
in remyelinating oligodendrocytes at the recovery stage of
EAE facilitated oligodendrocyte regeneration and remyeli-
nation in EAE demyelinated lesions. Our previous work
demonstrated that PDGFaR-positive OPCs and inﬂam-
matory cells (T cells and microglia/macrophages) do not
express the transgene product, Fv2E-PERK, in PLP/Fv2E-
PERK mice11 and that AP20187 treatment does not affect
the proliferation of OPCs or the activity of inﬂammatory
cells in mice undergoing EAE.11 Consistent with these re-
sults, we found that PERK activation in (re)myelinating
oligodendrocytes had no noticeable effect on OPCs or in-
ﬂammatory cells. Although the precise molecular mecha-
nisms by which PERK signaling protects remyelinating
oligodendrocytes against inﬂammatory mediators and ER
stress in immune-mediated demyelinating diseases remain
to be elucidated, the results presented herein suggest that the
manipulation of PERK signaling in remyelinating oligo-
dendrocytes could promote myelin repair in MS demyeli-
nated lesions.
IFN-g is thought to be a major contributing factor to poor
remyelination in MS lesions.1,13 Our previous studies have
shown that the deleterious effects of IFN-g on develop-
mental myelination and remyelination are mediated, at least
in part, by PERK signaling.14,15,18 The data concerning the
effects of PERK signaling, however, appear contradictory.
We showed that PERK haploinsufﬁciency exacerbated IFN-
geinduced myelinating oligodendrocyte loss and hypo-
myelination in young, developing mice and IFN-geinduced
remyelinating oligodendrocyte apoptosis and remyelination
failure in the cuprizone model.14,15 In contrast, although our
previous publication showed that global inactivation of the
GADD34 gene, which encodes the stress-inducible reg-
ulatory subunit of a phosphatase complex that dephos-
phorylates eIF2a, increased the activity of the PERK-eIF2a
pathway and ameliorated IFN-geinduced myelinating
oligodendrocyte loss and hypomyelination in young,
developing mice,18 we found that GADD34 inactivation
exacerbated IFN-geinduced remyelinating oligodendrocyte
death and remyelination failure in cuprizone-induced
demyelinated lesions (unpublished data, W. Lin). It is
known that IFN-g inﬂuences the viability of oligodendro-
cytes in the CNS by regulating the functions of T cells and
microglia/macrophages.28,29 Moreover, recent studies have
shown that PERK signaling is a potent regulator of the
functions of T cells and macrophages in inﬂammatory dis-
eases.30,31,49 Clearly, the mouse models used in our previ-
ous studies did not allow us to determine the speciﬁc
contribution of oligodendrocytes or inﬂammatory cells (T
cells and microglia/macrophages) to the contradictory ef-
fects of PERK signaling on developmental myelination and
remyelination in response to IFN-g. By using a transgenic
mouse model that allows for the temporally controlled
activation of PERK signaling speciﬁcally in oligodendro-
cytes, we showed herein that PERK activation in bothThe American Journal of Pathology - ajp.amjpathol.orgmyelinating oligodendrocytes and remyelinating oligoden-
drocytes is beneﬁcial in response to IFN-g. Therefore, we
demonstrated that PERK activation in (re)myelinating
oligodendrocytes protects these cells cell-autonomously
against the cytotoxicity of IFN-g, resulting in enhanced (re)
myelination. In addition, these results suggest that the
antagonistic effects of PERK signaling on developmental
myelination and remyelination in response to IFN-g are
likely the result of PERK’s effects on inﬂammatory cells (T
cells or microglia/macrophages).
The principle function of oligodendrocytes is to produce
myelin, the unique multilamellar sheath that wraps around
axons, in the CNS.25 Because of the enormous surface area
of myelin, each (re)myelinating oligodendrocyte must syn-
thesize a large quantity of myelin proteins during the active
phase of myelination.50 Recent studies have suggested that
oligodendrocytes are highly sensitive to the disruption of
protein translation.4,51 There is evidence that loss-of-
function mutations of translation initiation factor, eIF2B,
exclusively affect the CNS white matter in most cases of
vanishing white matter disease, a fatal autosomal-recessive
hypomyelinating disease.52,53 Although PERK activation
protects cells against cytotoxic effects of inﬂammatory
mediators and ER stress by phosphorylating eIF2a,11,22
p-eIF2a inhibits global protein biosynthesis by suppress-
ing the activity of eIF2B, with the two proteins forming a
non-productive p-eIF2aeeIF2B complex.54 Therefore, it
was necessary to exclude the possibility that PERK activa-
tion promotes (re)myelinating oligodendrocyte survival but
impairs their myelinating function. Importantly, we showed
herein that PERK activation in (re)myelinating oligoden-
drocytes did not suppress the (re)myelination process under
normal or pathological conditions. A previous study had
shown that AP20187 can penetrate the blood-brain barrier;
however, its blood-brain barrier permeability is moderate.55
Thus, our data likely suggest that the treatment with a low
dosage of AP20187 (0.5 or 2 mg/kg) moderately activates
PERK signaling in oligodendrocytes in PLP/Fv2E-PERK
mice and that moderate activation of PERK signaling has no
signiﬁcant effect on the function of remyelinating oligo-
dendrocytes in immune-mediated demyelinating diseases.
On the other hand, it could be interesting to determine
whether strong activation of PERK signaling in myelinating
oligodendrocytes would lead to oligodendrocyte dysfunc-
tion, reproducing vanishing white matter disease in mice.
Although we showed herein that enhanced PERK acti-
vation in remyelinating oligodendrocytes promoted remye-
lination in EAE demyelinated lesions, we found that starting
AP20187 treatment on PID20 did not signiﬁcantly affect the
severity of the clinical symptoms in PLP/Fv2E-PERK mice
during the recovery stage of disease. It is believed that
inﬂammation contributes signiﬁcantly to the clinical symp-
toms of EAE.56 Recent studies also suggest that axon
degeneration contributes to the clinical symptoms of MS
and EAE and is the principal cause of chronic disability in
MS.57,58 Axon degeneration largely occurs during the acute517
Lin et alstage of EAE. It is not surprising that enhanced PERK
activation in oligodendrocytes at the recovery stage of dis-
ease did not alter the degree of axon loss in EAE demye-
linated lesions (Figure 7E and Supplemental Figure S3,
DeF). Moreover, we showed that starting AP20187 treat-
ment on PID20 did not alter the degree of inﬂammation
in PLP/Fv2E-PERK mice at the recovery stage of
EAE. Therefore, it is possible that the lack of effect of
oligodendrocyte-speciﬁc enhancement of PERK activation
on inﬂammation and axon loss in EAE mice is responsible
for the minimal change in the clinical symptoms at the re-
covery stage of the disease. Clearly, the inability of
enhanced PERK activation in oligodendrocytes to amelio-
rate EAE clinical symptoms, despite its beneﬁcial effects on
remyelination, is deserving of additional study.
In summary, the results presented herein demonstrate that
activation of PERK signaling in remyelinating oligoden-
drocytes cell-autonomously promotes cell survival, and
subsequently results in enhanced remyelination in immune-
mediated demyelinating diseases. Currently, there is no
effective therapy for MS that promotes oligodendrocyte
regeneration and myelin repair. This study suggests that
therapeutic strategies that activate PERK signaling in
remyelinating oligodendrocytes may have beneﬁcial effects
on the restoration of neurological function and may delay
disability progression in patients with MS.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.10.009.References
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